Giorgio Armani has passed, What was found in Peru, Montell Jordan news, Elvis would be angry, glow in the dark plants and more.

The fifth annual ZERO Prostate Cancer Support Group Leader & MENtor Training enriched over 100 participants with skills, insights, and community support necessary for effective leadership.

Johnson & Johnson's Phase 3 PROTEUS study reveals ERLEADA® can significantly enhance prostate cancer treatment by reducing metastasis risk and improving outcomes.

MEDSIR reveals promising results from the ZZ-FIRST study, showing that combined therapy improves disease management in hormone-sensitive prostate cancer.

AstraZeneca partners with ZERO Prostate Cancer in the initiative 'Blitz the Barriers', striving to save 100,000 lives by tackling prostate cancer disparities.

A recent study highlights that 35.5% of men still experience urinary incontinence three years post-prostate cancer surgery, revealing significant gaps in awareness about treatment options.

Breast cancer month, domestic violence and prostate cancer, Halloween Gothic quotes and more.  Check out our book Empower Your Journey A Prostate Cancer Guidebook by Elizabeth Jordan and Daniel Jordan.

GI Innovation has formed a collaboration with Johnson & Johnson to assess an innovative combination therapy for prostate cancer, marking a significant advancement.

Caris Life Sciences has unveiled PTEN IHC testing following FDA approval, enhancing precision oncology in metastatic prostate cancer management.

The latest findings from the SECuRE trial reveal that 92% of pre-chemo participants experience significant PSA drops, advancing to the Cohort Expansion Phase.

A groundbreaking study conducted by UCLA researchers has uncovered a potential breakthrough in the treatment of prostate cancer. The research, published in a leading medical journal, focuses on a novel strategy that could significantly improve existing therapies. By targeting specific molecular pathways involved in tumor growth, the proposed approach aims to enhance the efficacy of current treatments while reducing side effects. This development comes amid growing global efforts to combat prostate cancer, which remains one of the most common malignancies among men. The study's findings suggest that combining traditional therapies with this new method could lead to better patient outcomes. Additionally, the research highlights the importance of personalized medicine in oncology, as the strategy was tested on diverse patient populations. While further clinical trials are needed to confirm its effectiveness, the potential impact of this discovery is substantial. The study also mentions a related finding about dietary fructose and ovarian cancer progression, underscoring the complex interplay between diet and cancer development. These results could pave the way for more targeted treatments across various cancers, marking a significant step forward in medical research.

Avenda Health's Unfold AI is now at Arizona Urology, transforming prostate cancer treatment with precision mapping. This innovation promises enhanced surgical planning and patient care.

Edward Stourton, a respected BBC broadcaster and journalist known for his work on Radio 4's Today programme, has passed away at the age of 68. Diagnosed with prostate cancer in 2014, he died surrounded by family, with the BBC confirming his death in a statement. Colleagues and friends praised his 'warm intelligence and wit', with Radio 4 controller Mohit Bakaya calling him 'absolutely outstanding'. His career spanned over four decades, including roles at ITN, BBC News, and Radio 4, where he hosted programmes like The World At One and Sunday. Stourton's work covered global events, from reporting on 9/11 to documentaries on the Catholic Church. His memoir revealed his long battle with cancer, which became incurable. Tributes highlighted his dedication, sharp mind, and influence on broadcasting. Survived by his wife, two sons, a daughter, and a step-daughter, Stourton leaves a legacy of journalistic excellence and integrity.

The National Comprehensive Cancer Network has awarded funding to projects aimed at enhancing the quality of care for metastatic prostate cancer patients, tackling significant disparities.

At Davos Healthcare, 5Q Spectra will unveil its clinical program for the PSB blood test, aimed at revolutionizing prostate cancer detection and management.

As ProCure Proton Therapy Center highlights National Prostate Cancer Awareness Month, learn why 'normal' PSA readings can be misleading, emphasizing proactive health measures.

A recent survey by MedStar Health indicates that many men over 55 are missing crucial prostate cancer screenings, highlighting a significant health concern.

The non-metastatic prostate cancer market is projected to grow at a CAGR of 4% from 2026 to 2036 due to advancements in therapies and increased disease awareness. Explore insights on treatment practices and emerging therapies driving this growth.

Labcorp has introduced the VENTANA PTEN (SP218) Assay, the first FDA-approved diagnostic for identifying prostate cancer patients eligible for advanced therapy.

AdvanCell has successfully raised $315 million, aimed at developing targeted therapies to fight prostate cancer, with plans for expansion.

The metastatic castration-resistant prostate cancer market is on the verge of robust growth by 2036, driven by advanced treatments and increasing cases.

Blue Earth Therapeutics, in partnership with UCL, expands cancer treatment options by initiating a Phase 1 trial for Actinium-based therapy in prostate cancer patients.

Join our mission to support Prostate Cancer UK. Learn how we’re donating 10% of profits from our Journals of a Lifetime range.

The method nearly doubles the proportion of men who maintain erectile function after prostate cancer surgery